The vascular endothelium and coagulation: homeostasis, disease, and treatment, with a focus on the von willebrand factor and factors VIII and V

JAD Pablo-Moreno, LJ Serrano, L Revuelta… - International Journal of …, 2022 - mdpi.com
The vascular endothelium has several important functions, including hemostasis. The
homeostasis of hemostasis is based on a fine balance between procoagulant and …

Acquired hemophilia A: current guidance and experience from clinical practice

AM Pishko, BS Doshi - Journal of blood medicine, 2022 - Taylor & Francis
In acquired hemophilia A (AHA), autoantibodies to coagulation factor VIII (FVIII) neutralize
FVIII activity leading to a potentially severe bleeding diathesis that carries a high rate of …

Emicizumab for the treatment of acquired hemophilia A

P Knoebl, J Thaler, P Jilma… - Blood, The Journal …, 2021 - ashpublications.org
Acquired hemophilia A (AHA) is a severe bleeding disorder caused by inhibiting
autoantibodies to coagulation factor VIII (FVIII). For hemostatic treatment, bypassing agents …

Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study

A Tiede, C Hart, P Knöbl, R Greil… - The Lancet …, 2023 - thelancet.com
Background Acquired haemophilia A is caused by neutralising autoantibodies against
coagulation factor VIII, leading to severe bleeding. Standard treatment involves …

Single‐dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: A multicenter, open …

PJ Wang, R Zhou, F Xue, H Zhou, J Bai… - American Journal of …, 2024 - Wiley Online Library
Acquired hemophilia A (AHA) is a rare but serious bleeding disorder. Randomized
controlled trial (RCT) comparing the efficacy of immunosuppression therapy for AHA lacks …

Genetic causes of haemophilia in women and girls

CH Miller, CJ Bean - Haemophilia, 2021 - Wiley Online Library
Women and girls reported as “haemophilic females” may have complex genetic causes for
their haemophilia phenotype. In addition, women and girls may have excessive bleeding …

Off‐label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: a sco** review of the literature

VM Thomas, MY Abou‐Ismail, MY Lim - Haemophilia, 2022 - Wiley Online Library
Introduction Since the approval of emicizumab, a bispecific, factor VIII‐mimetic antibody, for
use in persons with congenital haemophilia A in 2018, there have been increasing case …

Management of acquired hemophilia A: results from the Spanish registry

ME Mingot-Castellano, J Pardos-Gea, S Haya… - Blood …, 2021 - ashpublications.org
Abstract The Spanish Acquired Hemophilia A (AHA) Registry is intended to update the
status of AHA in Spain. One hundred and fifty-four patients were included and …

[HTML][HTML] Results of genetic analysis of 11 341 participants enrolled in the My Life, Our Future hemophilia genoty** initiative in the United States

JM Johnsen, SN Fletcher, A Dove, H McCracken… - Journal of Thrombosis …, 2022 - Elsevier
Abstract Background Hemophilia A (HA) and hemophilia B (HB) are rare inherited bleeding
disorders. Although causative genetic variants are clinically relevant, in 2012 only 20% of …

Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study

K Holstein, X Liu, A Smith, P Knöbl… - Blood, The Journal …, 2020 - ashpublications.org
Acquired hemophilia A (AHA) is due to autoantibodies against coagulation factor VIII (FVIII)
and most often presents with unexpected bleeding. In contrast to congenital hemophilia, the …